Monopar Therapeutics Inc. has released its financial results and recent developments for the third quarter of 2025, showcasing significant progress and changes compared to the same period in 2024.
Regarding the company's cash position, as of September 30, 2025, Monopar held $143.7 million in cash, cash equivalents, and investments. This is a notable increase from the third quarter of 2024, indicating a strong financial position.
However, the net loss for the third quarter of 2025 was $3.4 million or $0.48 per share, compared to a net loss of $1.3 million or $0.37 per share for the third quarter of 2024. This demonstrates a significant increase in net loss compared to the previous period.
In terms of research and development (R&D) expenses, there was a substantial rise in spending. R&D expenses for the third quarter of 2025 were $2,589,749, compared to $984,278 for the third quarter of 2024, representing an increase of $1,605,471. This increase was attributed to various factors, including manufacturing activities related to alxn1840 and personnel expenses.
Similarly, general and administrative (G&A) expenses also saw a significant jump. G&A expenses for the third quarter of 2025 were $1,503,326, compared to $590,624 for the third quarter of 2024, reflecting an increase of $912,702. This increase was primarily due to higher board compensation, personnel expenses, and other G&A expenses.
On a positive note, interest income for the third quarter of 2025 saw a substantial increase of $556,129 compared to the same period in 2024. This increase was attributed to interest earned on U.S. Treasury securities and higher bank balances following the approximately $91.9 million raised in the offering after accounting for the share repurchase and deducting underwriting discounts and commissions.
These financial figures demonstrate the shifts and developments in Monopar's financial performance and spending compared to the third quarter of 2024. Additionally, the company highlighted significant advancements in its clinical-stage programs, particularly with alxn1840 for Wilson disease and its radiopharmaceutical programs, indicating a strong focus on innovation and growth in its core therapeutic areas. As a result of these announcements, the company's shares have moved 2.83% on the market, and are now trading at a price of $84.92. For more information, read the company's full 8-K submission here.
